HeartMate 3风险评分的一项多中心评估
该研究在美国7个中心回顾性纳入2017至2021年接受HeartMate 3左心室辅助装置植入且随访至少1年的521例患者,评估HM3RS对1年死亡的风险区分度,并按MOMENTUM 3试验入组标准分层。全队列1年与2年生存率分别为85%和81%;HM3RS在全队列的AUC为0.63,符合入组标准者AUC为0.69,不符合者为0.58。
要点
- 全队列1年与2年生存率分别为85%和81%。
- 符合与不符合MOMENTUM 3入组标准者1年生存率87% vs 83%(p=0.21),2年生存率80% vs 78%(p=0.39),无统计学显著差异。
- HM3RS在全队列1年生存AUC为0.63,符合入组标准者AUC为0.69,不符合者AUC为0.58。
核心结论
- 在真实世界多中心队列中,无论是否符合MOMENTUM 3试验入组标准,商业HM3 LVAD植入后1年和2年生存率均极佳。
- HM3RS在「类试验」患者中提供了足够的风险区分度,但在不符合试验标准的患者中预测价值降低。
研究设计与样本
- 回顾性分析2017至2021年在美国7个中心接受HM3 LVAD植入且随访至少1年的521例患者。
- 根据MOMENTUM 3研究的入组与排除标准回顾性评估患者是否符合试验入组条件。
- 采用时间依赖受试者工作特征曲线分析评估HM3RS对全队列1年死亡的风险区分度,并按MOMENTUM 3试验入组资格分层。
- 依据HM3RS风险分类构建Kaplan-Meier曲线。
主要发现
- 521例患者中266例(51.1%)符合MOMENTUM 3入组标准。
- 全队列1年和2年生存率分别为85%和81%。
- 符合与不符合入组标准者1年生存率87% vs 83%(p=0.21),2年生存率80% vs 78%(p=0.39),均无统计学显著差异。
- 全队列HM3RS预测1年生存的AUC为0.63(95%CI:0.57-0.69,p<0.001)。
- 符合入组标准者AUC为0.69(95%CI:0.61-0.77,p<0.001),不符合者AUC为0.58(95%CI:0.49-0.66,p=0.078)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Heartmate 3 (HM3) risk score (HM3RS) was derived and validated internally from within the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) trial population and provides 1- and 2-year mortality risk prediction for patients in those before HM3 left ventricular assist device (LVAD) implantation. We aimed to evaluate the HM3RS in nontrial unselected patients, including those not meeting inclusion criteria for MOMENTUM 3 trial enrollment. METHODS: Patients who underwent HM3 LVAD implant at 1 of 7 US centers between 2017 and 2021, with at least 1-year follow-up, were included in this analysis. Patients were retrospectively assessed for their eligibility for the MOMENTUM 3 trial based on study inclusion and exclusion criteria. HM3RS risk discrimination was evaluated using time-dependent receiver operating characteristic curve analysis for 1-year mortality for all patients and further stratified by MOMENTUM 3 trial eligibility. Kaplan-Meier curves were constructed using the HM3RS-based risk categories. RESULTS: Of 521 patients included in the analysis, 266 (51.1%) would have met enrollment criteria for MOMENTUM 3. The 1- and 2-year survival for the total cohort was 85% and 81%, respectively. There was no statistically significant difference in survival between those who met and did not meet enrollment criteria at 1 (87% vs 83%; p = 0.21) and 2 years postimplant (80% vs 78%; p = 0.39). For the total cohort, HM3RS predicted 1-year survival with an area under the curve (AUC) of 0.63 (95% confidence interval [CI]: 0.57-0.69, p < 0.001). HM3RS performed better in the subset of patients meeting enrollment criteria: AUC 0.69 (95% CI:0.61-0.77, p < 0.001) compared to the subset that did not: AUC 0.58 (95% CI: 0.49-0.66, p = 0.078). CONCLUSIONS: In this real-world evidence, multicenter cohort, 1- and 2-year survival after commercial HM3 LVAD implant was excellent, regardless of trial eligibility. The HM3RS provided adequate risk discrimination in "trial-like" patients, but predictive value was reduced in patients who did not meet trial criteria.
引用
- Grewal J, Tripathi N, Bortner B, et al. A multicenter evaluation of the HeartMate 3 risk score. J Heart Lung Transplant. 2023. PMID: 38061468. doi:10.1016/j.healun.2023.11.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。